Evidence map›Paper›PMID 28029796›Full record

ArticleJournal of natural products2017

Identification of Neuroprotective Spoxazomicin and Oxachelin Glycosides via Chemoenzymatic Glycosyl-Scanning.

Jianjun Zhang, Ryan R Hughes, Meredith A Saunders, Sherif I Elshahawi, Larissa V Ponomareva, Yinan Zhang, Sydney R Winchester, Samantha A Scott, Manjula Sunkara, Andrew J Morris and 3 more

Abstract read
In one paragraph

Article in Journal of natural products, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.5field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. OleD Loki as a Catalyst for Hydroxamate Glycosylation.Chembiochem : a European journal of chemical biology · 2020
    Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

Jianjun ZhangCenter for Pharmaceutical Research and Innovation, College of Pharmacy, ‡Department of Pharmaceutical Sciences, College of Pharmacy, §Department of Psychology and Spinal Cord and Brain Injury Research Center, and ∥Division of Cardiovascular Medicine, University of Kentucky , Lexington, Kentucky 40536, United States.
Ryan R HughesCenter for Pharmaceutical Research and Innovation, College of Pharmacy, ‡Department of Pharmaceutical Sciences, College of Pharmacy, §Department of Psychology and Spinal Cord and Brain Injury Research Center, and ∥Division of Cardiovascular Medicine, University of Kentucky , Lexington, Kentucky 40536, United States.
Meredith A SaundersCenter for Pharmaceutical Research and Innovation, College of Pharmacy, ‡Department of Pharmaceutical Sciences, College of Pharmacy, §Department of Psychology and Spinal Cord and Brain Injury Research Center, and ∥Division of Cardiovascular Medicine, University of Kentucky , Lexington, Kentucky 40536, United States.
Sherif I ElshahawiCenter for Pharmaceutical Research and Innovation, College of Pharmacy, ‡Department of Pharmaceutical Sciences, College of Pharmacy, §Department of Psychology and Spinal Cord and Brain Injury Research Center, and ∥Division of Cardiovascular Medicine, University of Kentucky , Lexington, Kentucky 40536, United States.
Larissa V PonomarevaCenter for Pharmaceutical Research and Innovation, College of Pharmacy, ‡Department of Pharmaceutical Sciences, College of Pharmacy, §Department of Psychology and Spinal Cord and Brain Injury Research Center, and ∥Division of Cardiovascular Medicine, University of Kentucky , Lexington, Kentucky 40536, United States.
Yinan ZhangCenter for Pharmaceutical Research and Innovation, College of Pharmacy, ‡Department of Pharmaceutical Sciences, College of Pharmacy, §Department of Psychology and Spinal Cord and Brain Injury Research Center, and ∥Division of Cardiovascular Medicine, University of Kentucky , Lexington, Kentucky 40536, United States.
Sydney R WinchesterCenter for Pharmaceutical Research and Innovation, College of Pharmacy, ‡Department of Pharmaceutical Sciences, College of Pharmacy, §Department of Psychology and Spinal Cord and Brain Injury Research Center, and ∥Division of Cardiovascular Medicine, University of Kentucky , Lexington, Kentucky 40536, United States.
Samantha A ScottCenter for Pharmaceutical Research and Innovation, College of Pharmacy, ‡Department of Pharmaceutical Sciences, College of Pharmacy, §Department of Psychology and Spinal Cord and Brain Injury Research Center, and ∥Division of Cardiovascular Medicine, University of Kentucky , Lexington, Kentucky 40536, United States.
Manjula SunkaraCenter for Pharmaceutical Research and Innovation, College of Pharmacy, ‡Department of Pharmaceutical Sciences, College of Pharmacy, §Department of Psychology and Spinal Cord and Brain Injury Research Center, and ∥Division of Cardiovascular Medicine, University of Kentucky , Lexington, Kentucky 40536, United States.
Andrew J MorrisCenter for Pharmaceutical Research and Innovation, College of Pharmacy, ‡Department of Pharmaceutical Sciences, College of Pharmacy, §Department of Psychology and Spinal Cord and Brain Injury Research Center, and ∥Division of Cardiovascular Medicine, University of Kentucky , Lexington, Kentucky 40536, United States.
Mark A PrendergastCenter for Pharmaceutical Research and Innovation, College of Pharmacy, ‡Department of Pharmaceutical Sciences, College of Pharmacy, §Department of Psychology and Spinal Cord and Brain Injury Research Center, and ∥Division of Cardiovascular Medicine, University of Kentucky , Lexington, Kentucky 40536, United States.
Khaled A ShaabanCenter for Pharmaceutical Research and Innovation, College of Pharmacy, ‡Department of Pharmaceutical Sciences, College of Pharmacy, §Department of Psychology and Spinal Cord and Brain Injury Research Center, and ∥Division of Cardiovascular Medicine, University of Kentucky , Lexington, Kentucky 40536, United States.
Jon S ThorsonCenter for Pharmaceutical Research and Innovation, College of Pharmacy, ‡Department of Pharmaceutical Sciences, College of Pharmacy, §Department of Psychology and Spinal Cord and Brain Injury Research Center, and ∥Division of Cardiovascular Medicine, University of Kentucky , Lexington, Kentucky 40536, United States.ORCID 0000-0002-7148-0721
University of Kentucky · US

Funding

Kentucky Center for Clinical and Translational ScienceUL1TR001998 · NCATS · UNIVERSITY OF KENTUCKY · PI HARTMANN, KATHERINE E, KERN, PHILIP A · 2016 to 2025
$34.2M
The role of IKKß in linking obesity to adipose tissue inflammation and adipogeneP20GM103527 · NIGMS · UNIVERSITY OF KENTUCKY · PI MORRIS, ANDREW J · 2012 to 2017
$13.7M
Kentucky Center for Clinical and Translational ScienceUL1TR000117 · NCATS · UNIVERSITY OF KENTUCKY · PI KERN, PHILIP A · 2012 to 2015
$13.3M
Training in Drug Abuse Related Research.T32DA016176 · NIDA · UNIVERSITY OF KENTUCKY · PI DWOSKIN, LINDA P · 2004 to 2020
$4.0M
In Vitro Glycorandomization of Natural ProductsR37AI052218 · NIAID · UNIVERSITY OF KENTUCKY · PI THORSON, JON SCOTT · 2012 to 2021
$4.0M
NCATS NIH HHS UL1 TR000117NCATS NIH HHS UL1 TR001998NIAID NIH HHS R37 AI052218NIDA NIH HHS T32 DA016176NIGMS NIH HHS P20 GM103527
6 · The paper itself

Abstract

The assessment of glycosyl-scanning to expand the molecular and functional diversity of metabolites from the underground coal mine fire-associated Streptomyces sp. RM-14-6 is reported. Using the engineered glycosyltransferase OleD Loki and a 2-chloro-4-nitrophenylglycoside-based screen, six metabolites were identified as substrates of OleD Loki, from which 12 corresponding metabolite glycosides were produced and characterized. This study highlights the first application of the 2-chloro-4-nitrophenylglycoside-based screen toward an unbiased set of unique microbial natural products and the first reported application of the 2-chloro-4-nitrophenylglycoside-based transglycosylation reaction for the corresponding preparative synthesis of target glycosides. Bioactivity analysis (including antibacterial, antifungal, anticancer, and EtOH damage neuroprotection assays) revealed glycosylation to attenuate the neuroprotective potency of 4, while glycosylation of the structurally related inactive spoxazomicin C (3) remarkably invoked neuroprotective activity.

Indexed as

Antifungal AgentsGlycosidesGlycosylationMolecular StructureNeuroprotective AgentsOligopeptidesOxazolesStreptomycesAntifungal AgentsGlycosidesNeuroprotective AgentsOligopeptidesoxachelinOxazolesspoxazomicin C

Identifiers

PMID28029796
PMCPMC5337260
OpenAlexW2565933524

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.